Format
Sort by
Items per page

Send to

Choose Destination

Best matches for multiple sclerosis AND ("QT" OR Torsad*):

Search results

Items: 1 to 20 of 34

1.

A Thorough QT/QTc Study With Laquinimod, a Novel Immunomodulator in Development for Multiple Sclerosis and Huntington Disease.

Spiegelstein O, Mimrod D, Rabinovich L, Eyal E, Sprenger C, Elgart A, Samara E, Morganroth J.

Clin Pharmacol Drug Dev. 2018 May 22. doi: 10.1002/cpdd.442. [Epub ahead of print]

PMID:
29786964
2.

Cardiac repolarization during fingolimod treatment in patients with relapsing-remitting multiple sclerosis.

Laiho A, Laitinen TM, Hartikainen P, Hartikainen JEK, Laitinen TP, Simula S.

Brain Behav. 2018 Jan 30;8(2):e00925. doi: 10.1002/brb3.925. eCollection 2018 Feb.

3.

Cardiac repolarization evolves differently during the course of benign and disabling multiple sclerosis.

Mikkola A, Ojanen A, Hartikainen JE, Remes AM, Simula S.

Mult Scler Relat Disord. 2018 Feb;20:205-209. doi: 10.1016/j.msard.2018.01.029. Epub 2018 Feb 1.

PMID:
29428463
4.

Cardiac Safety of Ozanimod, a Novel Sphingosine-1-Phosphate Receptor Modulator: Results of a Thorough QT/QTc Study.

Tran JQ, Hartung JP, Olson AD, Mendzelevski B, Timony GA, Boehm MF, Peach RJ, Gujrathi S, Frohna PA.

Clin Pharmacol Drug Dev. 2018 Mar;7(3):263-276. doi: 10.1002/cpdd.383. Epub 2017 Aug 7.

5.

The impact of multiple sclerosis onset symptom on cardiac repolarization.

Mikkola A, Ojanen A, Hartikainen JEK, Remes AM, Simula S.

Brain Behav. 2017 Jun 5;7(7):e00742. doi: 10.1002/brb3.742. eCollection 2017 Jul.

6.

Fingolimod (Gilenya® ) in multiple sclerosis: bradycardia, atrioventricular blocks, and mild effect on the QTc interval. Something to do with the L-type calcium channel?

Pilote S, Simard C, Drolet B.

Fundam Clin Pharmacol. 2017 Aug;31(4):392-402. doi: 10.1111/fcp.12284. Epub 2017 Apr 26.

PMID:
28299825
7.

QTc interval in patients with multiple sclerosis: an inference from the insula of Reil?

Turri G, Calabrese M, Pancheri E, Monaco S, Gajofatto A, Marafioti V.

Eur J Neurol. 2017 Mar;24(3):491-496. doi: 10.1111/ene.13229. Epub 2017 Jan 23.

PMID:
28111831
8.

GRAPE: a graphical pipeline environment for image analysis in adaptive magnetic resonance imaging.

Gabr RE, Tefera GB, Allen WJ, Pednekar AS, Narayana PA.

Int J Comput Assist Radiol Surg. 2017 Mar;12(3):449-457. doi: 10.1007/s11548-016-1495-z. Epub 2016 Oct 28. Erratum in: Int J Comput Assist Radiol Surg. 2017 Mar;12 (3):459.

10.

Tp-Te interval predicts heart rate reduction after fingolimod administration in patients with multiple sclerosis.

Tocci G, Giuliani M, Canichella F, Timpano J, Presta V, Francia P, Musumeci MB, Fubelli F, Pozzilli C, Volpe M, Ferrucci A.

Int J Cardiol. 2016 Oct 15;221:881-5. doi: 10.1016/j.ijcard.2016.07.134. Epub 2016 Jul 9.

PMID:
27434365
11.

AVN-101: A Multi-Target Drug Candidate for the Treatment of CNS Disorders.

Ivachtchenko AV, Lavrovsky Y, Okun I.

J Alzheimers Dis. 2016 May 25;53(2):583-620. doi: 10.3233/JAD-151146. Review.

12.

P wave duration and dispersion and QT interval in multiple sclerosis.

Razazian N, Hedayati N, Moradian N, Bostani A, Afshari D, Asgari N.

Mult Scler Relat Disord. 2014 Sep;3(5):662-5. doi: 10.1016/j.msard.2014.05.001. Epub 2014 May 14.

PMID:
26265278
13.

Fingolimod first-dose effects in patients with relapsing multiple sclerosis concomitantly receiving selective serotonin-reuptake inhibitors.

Bermel RA, Hashmonay R, Meng X, Randhawa S, von Rosenstiel P, Sfikas N, Kantor D.

Mult Scler Relat Disord. 2015 May;4(3):273-80. doi: 10.1016/j.msard.2015.04.002. Epub 2015 Apr 13.

14.

Effect of ponesimod, a selective S1P1 receptor modulator, on the QT interval in healthy individuals.

Hoch M, Darpo B, Brossard P, Zhou M, Stoltz R, Dingemanse J.

Basic Clin Pharmacol Toxicol. 2015 May;116(5):429-37. doi: 10.1111/bcpt.12336. Epub 2014 Nov 8.

15.

Analysis of Onset Mechanisms of a Sphingosine 1-Phosphate Receptor Modulator Fingolimod-Induced Atrioventricular Conduction Block and QT-Interval Prolongation.

Yagi Y, Nakamura Y, Kitahara K, Harada T, Kato K, Ninomiya T, Cao X, Ohara H, Izumi-Nakaseko H, Suzuki K, Ando K, Sugiyama A.

Toxicol Appl Pharmacol. 2014 Nov 15;281(1):39-47. doi: 10.1016/j.taap.2014.09.006. Epub 2014 Sep 16.

PMID:
25223691
16.

Overview of mouse models of autism spectrum disorders.

Bey AL, Jiang YH.

Curr Protoc Pharmacol. 2014 Sep 2;66:5.66.1-26. doi: 10.1002/0471141755.ph0566s66. Review.

17.

Evaluating the safety and efficacy of dextromethorphan/quinidine in the treatment of pseudobulbar affect.

Schoedel KA, Morrow SA, Sellers EM.

Neuropsychiatr Dis Treat. 2014 Jun 26;10:1161-74. doi: 10.2147/NDT.S30713. eCollection 2014. Review.

18.

The autonomic balance predicts cardiac responses after the first dose of fingolimod.

Rossi S, Rocchi C, Studer V, Motta C, Lauretti B, Germani G, Macchiarulo G, Marfia GA, Centonze D.

Mult Scler. 2015 Feb;21(2):206-16. doi: 10.1177/1352458514538885. Epub 2014 Jun 23.

PMID:
24957049
19.

A Multiple-Dose, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group QT/QTc Study to Evaluate the Electrophysiologic Effects of THC/CBD Spray.

Sellers EM, Schoedel K, Bartlett C, Romach M, Russo EB, Stott CG, Wright S, White L, Duncombe P, Chen CF.

Clin Pharmacol Drug Dev. 2013 Jul;2(3):285-94. doi: 10.1002/cpdd.36. Epub 2013 May 14.

PMID:
27121791
20.

The safety profile of dalfampridine extended release in multiple sclerosis clinical trials.

Cornblath DR, Bienen EJ, Blight AR.

Clin Ther. 2012 May;34(5):1056-69. doi: 10.1016/j.clinthera.2012.03.007. Epub 2012 Apr 11. Review.

PMID:
22497693

Supplemental Content

Loading ...
Support Center